Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Long-Term Deferred Tax (2020 - 2023)

Lipocine (LPCN) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $43.0 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Deferred Tax rose 119400.57% year-over-year to $43.0 million, compared with a TTM value of $43.0 million through Dec 2021, up 119400.57%, and an annual FY2021 reading of $43.0 million, up 119400.57% over the prior year.
  • Long-Term Deferred Tax was $43.0 million for Q4 2021 at Lipocine, up from $36000.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $43.0 million in Q4 2021 and bottomed at $36000.0 in Q4 2020.